Tessera Therapeutics

We are excited that our team will be presenting at this year's Society for Immunotherapy of Cancer (SITC) Annual Meeting. If you are attending, please stop by our poster presentation to catch up on our latest advances towards novel T-cell based therapies. 

Today we announced new preclinical data presented at the 31st Annual Congress of the European Society of Gene and Cell Therapy, highlighting our progress towards in vivo therapies for alpha-1 antitrypsin deficiency (AATD) and sickle cell disease (SCD). Read more here: https://lnkd.in/empE-VQi

The European Society of Gene and Cell Therapy Annual Meeting begins tomorrow. We look forward to showcasing the continued advances of our #GeneWriting and lipid nanoparticle (LNP)-based delivery platforms. 

Celebrating the end of #HispanicHeritageMonth, we're inspired by the stories of our colleagues. Jason Rodriguez, Senior Director, Immune Oncology Process Sciences, shares how he is paving new paths and taking pride in his Hispanic heritage. #TeamTessera

Our team will be attending Meeting on the Mesa this week. Please check out Vikram Ranade's presentation and Anne-Virginie Eggimann's panel discussion. Learn more here: https://lnkd.in/eiUpMy4

Julio Lanzo, Research Associate II, reflects on what #HispanicHeritageMonth means to him.

In celebration of #HispanicHeritageMonth our colleagues are reflecting on the important contributions and influence of Hispanic heritage and culture. Ada Del Cid Oseguera, Senior Engineer I, shares how she lives our value of Community through her efforts to create a more equitable workplace. #TeamTessera

Thank you to Erin Harris for hosting our CEO, Mike Severino, on Cell & Gene: The Podcast. It was an insightful conversation discussing Tessera Therapeutics' mission, groundbreaking science, and our exciting preclinical progress across our programs. Catch the full episode here: https://bit.ly/4d4M0NQ

This week, our COO Hari Pujar, will be speaking at this year's RNA Leaders USA Conference. Learn more here: https://lnkd.in/dhTfJ4VB

In case you missed it, our CSO, Mike Holmes, recently spoke to @DrugTargetRev about the RNA #GeneWriters data we presented at #ASGCT2024. Read the article to learn more about the progress of our #GeneWriting platform in alpha-1 antitrypsin deficiency (AATD): https://lnkd.in/exCSwezU